Building on our previous analysis, which revealed that the expression levels of ZNF132 and ZNF671 were associated with the enrichment of immune-related pathways, we assessed immune scores in a matched cohort of 60 stage III CRC patients. Here, ZNF132 is linked to colorectal carcinoma.